admin – Page 7367 – Get News Story

Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

DelveInsight’s, “Multiple Myeloma Pipeline Insights 2024” report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Multiple Myeloma Pipeline Report

DelveInsight’s Multiple Myeloma pipeline report depicts a robust space with 75+ Multiple Myeloma companies working to develop 80+ pipeline therapies for Multiple Myeloma treatment.
The leading Multiple Myeloma Companies working in the market include CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
Promising Multiple Myeloma Pipeline Therapies in the various stages of development include TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.
December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for Cevostamab, Tocilizumab, Pomalidomide, Daratumumab and Dexamethasone. This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
December 2023: AbbVieannounced a study of Phase 3 clinical trials for Pomalidomide, Dexamethasone and Venetoclax. A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
December 2023: Regeneron Pharmaceuticals announced a study of Phase 1 clinical trials for Linvoseltamab, Daratumumab, Carfilzomib, Bortezomib and Isatuximab. The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after multiple prior therapies and needed to be treated again.

Request a sample and discover the recent advances in Multiple Myeloma Treatment Drugs @ Multiple Myeloma Pipeline Outlook Report

The Multiple Myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Multiple Myeloma clinical trial landscape.

Multiple Myeloma Overview

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal immunoglobulins. Unchecked, the excess production of these plasma cells can ultimately lead to specific end-organ damage. Most commonly, this is seen when at least one of the following clinical manifestations are present: hypercalcemia, renal dysfunction, anemia, or bone pain accompanied by lytic lesions.

Find out more about Multiple Myeloma Treatment Landscape @ Drugs for Multiple Myeloma Treatment

Multiple Myeloma Emerging Drugs Profile

Zevorcabtagene Autoleucel: Carsgen Therapeutics
Descartes 08: Cartesian Therapeutics
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics

Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 75+ key Multiple Myeloma companies which are developing the Multiple Myeloma therapies. The Multiple Myeloma companies which have their Multiple myeloma drug candidates in the most advanced stage, i.e Registered include Carsgen Therapeutics.

DelveInsight’s Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Multiple Myeloma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Multiple Myeloma Pipeline Therapies @ Multiple Myeloma Clinical Trials Assessment

Scope of the Multiple Myeloma Pipeline Report

Coverage- Global
Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Multiple Myeloma Companies- CASI Pharmaceuticals, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., Sorrento Therapeutics, TeneoOne, Karyopharma Therapeutics, Arcellx, Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Bristol Myers Squib, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech Co., Ltd., CRISPR Therapeutics, AstraZeneca, IGM Biosciences, Novartis, GlaxoSmithKline, Innovent Biologics, Keymed Biociences, Starton Therapeutics, Takeda, Fate Therapeutics, Gilead Sciences, Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Janssen Pharmaceutical, Nanjing IASO Biotechnology Co., Ltd., GPCR Therapeutics, Chimerix, and others.
Multiple Myeloma Pipeline Therapies- TNB-383B, belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Pomalidomide, Venetoclax, Bortezomib, BT062, Selinexor, Lenalidomide, Methylprednisolone, and others.

Dive deep into rich insights for new drugs for Multiple Myeloma treatment, Visit @ Multiple Myeloma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Multiple myeloma Executive Summary
Multiple myeloma Overview
Multiple myeloma Pipeline Therapeutics
Multiple myeloma Therapeutic Assessment
Multiple myeloma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Venetoclax: AbbVie
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PHE885: Novartis
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
ONC 201: Oncoceutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TNB 383B: TeneoBio
Drug profiles in the detailed report…..
Inactive Products
Multiple myeloma Companies
Multiple myeloma Products
Multiple myeloma Unmet Needs
Multiple myeloma Market Drivers and Barriers
Multiple myeloma Future Perspectives and Conclusion
Multiple myeloma Analyst Views
Multiple myeloma Companies
Appendix

For further information on the Multiple Myeloma pipeline therapeutics, reach out to Multiple Myeloma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

Getting to know the world of a manual tester becomes easy with Test Pro

The work of a manual tester is actually really serious and requires patience, but the main thing in this field is desire. And if you have a question: “What do we mean when we say “desire “?”, then our answer will surprise you. This is the desire to develop, the desire to become better every day, and most importantly, it is the desire to guarantee software security to everyone who needs it.

But what are the features and demand for this profession in our modern life and how can Test Pro help you? Let’s find out about it today!

What is the essence of the manual tester profession?

Let’s start with the fact that any software development process involves the work of a manual tester, because every new program must be tested manually before its testing can be automated. So what is the essence of this profession? If your dream is to become a manual tester, then be prepared for the fact that you will have to test the functionality of programs in detail, identify and document errors, and also make sure that these errors are resolved correctly. Therefore, when someone wants to discover an unexpected problem and sees that automation is ineffective, then this person should turn to manual testers for help.

Are manual testers in demand?

As we know, automated testers have gained more popularity than manual testers due to their efficiency and speed, but in reality, the demand for manual testers still exists today. This demand is used in several things, for example such as: exploratory testing, where all the creativity of the manual tester is used to identify defects; special testing, where there is a time limit and this limit can only be met by manual testers; and usability testing, where manual testers, thanks to their analytical skills, evaluate the user interaction and usability of the program.

Learn the ins and outs of manual testing with Test Pro

It doesn’t matter to us that you have never had experience in manual testing, or you just started in this field, or you already know a lot about this profession. It is important for us to give you what no one has ever been able to give you. We want to give you confidence in your analytical skills, we want to teach you all the useful things that exist in the profession of a manual tester, and we also want to provide you with the best future. You can get all this and more by taking our courses from Test Pro. This is the platform that is perfect for everyone, thanks to its user-friendly environment for learning manual testing.

If you choose Test Pro, then you can consider yourself a golden ticket to a happy life!

The benefits of choosing a manual testing course at Test Pro

There are several main reasons why choosing manual course from Test Pro is the right decision:

1. No age or other requirements

Test Pro offers you an inclusive learning environment where people of all ages or backgrounds are free to participate in manual tester training and contribute to the field.

2. No prior coding experience is required

Test Pro’s manual testing courses require you to focus on creating effective test scenarios without the need for extensive programming knowledge.

3. Completely online

If you are constantly busy, or you want to be able to combine work and study, or you just want to adjust your schedule to suit yourself, then you are in luck, because by choosing Test Pro, such an opportunity becomes a reality!

4. Experienced teaching staff in the field

Test Pro provides you with experienced instructors who bring real-world examples and practical insights into the learning environment, offering a more hands-on learning experience. In addition, your instructors act as mentors for you. These are people who will always support you until the end of the course.

5. The possibility of employment

Test Pro emphasizes job-ready skills and ensures that after completing the full manual testing course, you will be able to find a real job and earn from $35 per hour. Isn’t that cool?

As you can see, Test Pro is not an ordinary platform. This place works wonders in the field of software. If you really want to become a manual tester and you “have a fire in your eyes”, then we invite you to a free webinar where you can learn more useful information for you. If you are ready to take this first path to a happy life, then register for a course from Test Pro and you will understand everything yourself.

Media Contact
Company Name: Test Pro
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://testpro.io/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Getting to know the world of a manual tester becomes easy with Test Pro

Kathleen Cameron Selected as Top Business Innovator of the Year by IAOTP

Kathleen Cameron, Entrepreneur, Role Model, Best-Selling Author, World-Famous Manifestation Coach, Speaker, and Founder of Diamond Academy Coaching Inc. was recently selected as Top Business Innovator of the Year for 2024 by the International Association of Top Professionals (IAOTP) for her outstanding leadership, dedication, and commitment to the industry.

While inclusion with the International Association of Top Professionals is an honor, only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, other affiliations, and contributions to their communities. All honorees are invited to attend the IAOTP’s annual awards gala at the end of this year for a night to honor their achievements.

www.iaotp.com/award-gala

Kathleen’s extensive experience of over twenty years has solidified her reputation as a highly respected and accomplished professional. She has gained worldwide recognition for her expertise in her field and is admired for her strong leadership skills and track record of achieving remarkable outcomes. Kathleen is not only a mother but also a highly respected Success, Life, and Manifestation Coach with a track record of entrepreneurial success and best-selling authorship. In just three years, she has built a company worth $20 million. She generously shares her valuable knowledge and experience with everyone she meets. Ms Cameron started her leadership journey as a Registered Nurse before venturing into entrepreneurship by exploring and working in the coaching profession in 2017. She quickly realized she could work for herself and still be present with her two daughters. With this realization, she committed herself fully to constructing her empire.

Kathleen Cameron has significantly impacted numerous lives since she established Diamond Academy Coaching Inc. in January 2020. She has generated millions in income through her coaching programs and supporting courses. Additionally, she has co-written a book, authored her own book, made guest appearances on various podcasts and TV stations, and, most recently, launched her own podcast.

Before embarking on her career path, she graduated with two undergraduate degrees from the University of Windsor and a Master’s in Nursing Leadership from the University of Toronto.

Throughout her illustrious career, Kathleen has received awards, accolades, and worldwide recognition for her accomplishments. In 2023, Kathleen was awarded IAOTP’s Top Chief Wealth Creator of the Year and Empowered Woman of the Year and was featured on the famous Nasdaq Billboard in Times Square. This year, she will grace the front cover of TIP (Top Industry Professionals) Magazine. She will be honored at IAOTP’s annual awards gala at the magnificent Opryland Hotel in Nashville this December for her current selection as Top Business Innovator of the Year for 2024 by the International Association of Top Professionals.

Kathleen has accomplished remarkable achievements in her career, positively impacting the lives of over 100,000 individuals by helping them attract love, money, and success. She has achieved this through her strong belief, determination, and creative methods of manifesting and utilizing the Laws of Attraction. With her unique manifestation techniques and profound grasp of the Laws of Attraction, she has effectively built Diamond Academy Coaching, a widely respected global success network. This platform has enabled countless students to experience significant personal and professional development. Kathleen’s exceptional leadership has empowered countless individuals to achieve lives beyond their wildest dreams, and she is only getting started. Kathleen is committed to helping individuals unleash their full potential and become the best version of themselves. She skillfully assists individuals in attaining their objectives and pushing themselves to new levels of personal development. The book she wrote and published, Becoming The One, garnered significant acclaim when it was released in August 2021. The book gained immediate popularity, captivating readers across five countries on its first day. Cameron resides in Ontario, Canada, with her lovely daughters, Masyn and Raegan.

The President of IAOTP, Stephanie Cirami, declared, “Choosing Kathleen for this award was an easy decision for our panel to make. She is an incredible leader who consistently thinks outside the box and inspires and motivates individuals to push boundaries and overcome personal obstacles. We cannot wait to celebrate her at the gala.”

Looking back, Kathleen attributes her success to her perseverance, work ethic, and the mentors she has had along the way. When not working, she enjoys traveling and spending time with her family. In the future, she hopes to inspire and influence those getting into the field.

For more information, please visit: https://kathleencameronofficial.com/

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and help influence others in their fields. This organization is not a membership that anyone can join. You must be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTP’s experts have given thousands of top prestigious professionals worldwide the recognition and credibility they deserve and have helped build their branding empires. IAOTP prides itself on being a one-of-a-kind boutique networking organization that handpicks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For more information on IAOTP, please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

OWNx Unveils Revolutionary Precious Metals IRA with Zero Premiums and No Minimum Investment

Transforming the Precious Metals Investment Landscape: OWNx’s Latest Offering Promises More Metal, Less Hype, and Unprecedented Accessibility.

Lawrence, Kansas – Feb 21, 2024 – OWNx, a leading innovator in the precious metals investment sector, announced the launch of the OWNx Precious Metals IRA. This groundbreaking service offers investors a cost-effective, flexible, and secure way to invest in precious metals with zero premiums, no minimum investment requirement, and low fees. With over 32,000 account holders and more than $300 million in transactions, OWNx has set industry standards by eliminating the barriers typically associated with investing in precious metals.

OWNx proudly introduces the OWNx Precious Metals IRA, a cutting-edge investment option designed to improve access to gold, silver, platinum, and palladium retirement investments. Through its intuitive app and online dashboard, OWNx enables investors to set up and trade precious metals with unparalleled ease and efficiency. Unlike traditional Precious Metals IRAs, which often come with high premiums and restrictive minimum investments, OWNx’s IRA allows for fractional investing by weight, maximizing the amount of metal investors receive for their money. A recent publication as seen on Yahoo Finance confirms this new product.

Josh McCleary, Co-Founder of OWNx, stated, “Our mission was clear from the start: to tackle the inefficiencies and high costs plaguing the Precious Metals IRA market. By leveraging the OWNx technology platform, we’ve not only simplified the investment process but also ensured that our clients get more metal for their money, without any premiums or hidden fees. This is the future of precious metals investing.”

OWNx’s commitment to transparency and value is evident in its zero-premium policy, low fees, and at-cost trading mechanism, but OWNx goes even further, offering theirIRA customers zero premium trades on all OWNx transactions -both inside and outside of their IRA accounts. The company’s AAA rating by the Better Business Bureau and stellar reviews across platforms like Trustpilot and Google reflect its dedication to customer satisfaction and trust. With more than 32,000 account holders and a transaction volume exceeding $300 million, OWNx is at the forefront of redefining the precious metals investment experience.

About OWNx

OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for investing in gold, silver, platinum, and palladium. Since 2008, OWNx has been dedicated to making precious metals investment accessible, straightforward, and cost-effective for investors at all levels. With a focus on technology-driven solutions, OWNx provides automatic purchase options, secure storage, and instant trading capabilities, empowering individuals to diversify their portfolios with confidence.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: OWNx
Contact Person: Josh McCleary
Email: Send Email
Address:1425 Oread W Dr. STE 105
City: Lawrence
State: KS 66049
Country: United States
Website: https://ownx.com/

Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024

DelveInsight’s, “Non-Small-Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 135+ Non-Small Cell Lung Cancer Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
The leading Non-Small Cell Lung Cancer Companies working in the market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.
December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for V940 and Pembrolizumab. The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
December 2023: AstraZeneca announced a study of Phase 2 clinical trials for Durvalumab, Oleclumab, Monalizumab, MEDI5752, and AZD0171. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
December 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, and Cisplatin. The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.

Request a sample and discover the recent advances in Non-Small Cell Lung Cancer Treatment Drugs @ Non-Small Cell Lung Cancer Pipeline Outlook Report

The Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Non-Small Cell Lung Cancer clinical trial landscape.

Non-Small Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adenocancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs. It’s the most common kind of lung cancer among both smokers and nonsmokers and people under 45. It often grows more slowly than other lung cancers. b) Squamous cell lung cancer starts in cells that line the inner airways of the lungs.

Find out more about Non-Small Cell Lung Cancer Treatment Landscape @ Drugs for Non-Small Cell Lung Cancer Treatment

Non-Small Cell Lung Cancer Emerging Drugs Profile

Datopotamab deruxtecan: Daiichi Sankyo
JDQ443: Novartis
MRTX849: Mirati Therapeutics
INBRX-106: Inhibrx

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 135+ key Non-Small Cell Lung Cancer companies which are developing the Non-Small Cell Lung Cancer therapies. The Non-Small Cell Lung Cancer companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.

DelveInsight’s Non-Small Cell Lung Cancer Pipeline report covers around 150+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-Small-Cell Lung cancer Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride

Learn more about the emerging Non-Small Cell Lung Cancer Pipeline Therapies @ Non-Small Cell Lung Cancer Clinical Trials Assessment

Scope of the Non-Small Cell Lung Cancer Pipeline Report

Coverage- Global
Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Non-Small Cell Lung Cancer Companies- BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Dive deep into rich insights for new drugs for Non-Small Cell Lung Cancer treatment, Visit @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Non-Small Cell Lung Cancer Executive Summary
Non-Small-Cell Lung cancer Overview
Non-Small Cell Lung Cancer Pipeline Therapeutics
Non-Small Cell Lung Cancer Therapeutic Assessment
Non-Small-Cell Lung cancer DelveInsight’s Analytical Perspective
Mid Stage Products (Phase III)
Datopotamab deruxtecan: Daiichi Sankyo
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
RMC-4630: REVOLUTION Medicines
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
GB 1211: BridgeBio Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BBP 398: BridgeBio Pharma.
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Non-Small-Cell Lung Cancer Companies
Non-Small-Cell Lung Cancer Key Products
Non-Small-Cell Lung Cancer Unmet Needs
Non-Small-Cell Lung Cancer Market Drivers and Barriers
Non-Small-Cell Lung Cancer Future Perspectives and Conclusion
Non-Small-Cell Lung Cancer Analyst Views
Non-Small-Cell Lung Cancer Companies
Appendix

For further information on the Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024

Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

DelveInsight’s, “Acute Lymphocytic Leukemia Pipeline Insight 2024” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
The leading Acute Lymphocytic Leukemia companies working in the market include PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Life technology Co. Ltd., Celgene, and others.
Promising Acute Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.
December 2023: Curon Biopharmaceutical (Shanghai) Co. Ltd. announced a study of Phase 1 & 2 clinical trials for CN201. This study is designed in 2 parts as described below: Phase Ib (dose escalation and expansion) and Phase II. If in Phase Ib it is observed in adult subjects at doses with manageable risk and antitumor activity, studies in pediatric subjects can be initiated to explore safety and efficacy in pediatric subjects, as well as pharmacokinetic profiles.
December 2023: Takara Bio Inc. announced a study of Phase 1 & 2 clinical trials for TBI-1501. CD19-CAR-T will be administered in the split dose. Phase 2 recommended dose will be applied for phase 1 portion. The investigator assesses efficacy of CD19-CAR-T in accordance with study-specific criteria, at 8 week after the infusion of CD19-CAR-T (or at the time of termination). The investigator also assesses the safety during the follow-up period. Long-term follow-up study is conducted at frequency of once a year for 15 years after the infusion of CD19-CAR-T in reference to guidelines of FDA.
December 2023: Amgenannounced a study of Phase 3 clinical trials for Blinatumomab and SOC chemotherapy regimen. The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
December 2023: H. Lee Moffitt Cancer Center and Research Instituteannounced a study of Phase 2 clinical trials for Tecartus. This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy.

Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Treatment Drugs @ Acute Lymphocytic Leukemia Pipeline Outlook Report

In the Acute Lymphocytic Leukemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Acute Lymphocytic Leukemia clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Acute Lymphocytic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Acute Lymphocytic Leukemia Overview

Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. “”Lymphocytic”” means it develops from early (immature) forms of lymphocytes, a type of white blood cell.

Find out more about Acute Lymphocytic Leukemia Therapeutics Assessment @ Acute Lymphocytic Leukemia Preclinical and Discovery Stage Products

Acute Lymphocytic Leukemia Emerging Drugs Profile

CPX-351: Jazz Pharmaceuticals
JZP-458: Jazz Pharmaceuticals
UCART22: Cellectis
JZP-341: Jazz Pharmaceuticals

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 150+ key Acute Lymphocytic Leukemia companies which are developing the Acute Lymphocytic Leukemia pipeline therapies. The Acute Lymphocytic Leukemia companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others.

DelveInsight’s Acute Lymphocytic Leukemia Pipeline Report covers around 160+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion
Intradermal
Intramuscular
Intranasal
Intravenous
Oral
Parenteral
Subcutaneous.
Molecule Type

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as

Gene therapies
Small molecule
Vaccines
Polymers
Peptides
Monoclonal antibodies
Product Type

Learn more about the emerging Acute Lymphocytic Leukemia Pipeline Therapies @ Acute Lymphocytic Leukemia Clinical Trials Assessment

Scope of the Acute Lymphocytic Leukemia Pipeline Report

Coverage- Global
Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Acute Lymphocytic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
Acute Lymphocytic Leukemia Pipeline Therapies- Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.

Dive deep into rich insights for new drugs for Acute Lymphocytic Leukemia Treatment, Visit @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Acute Lymphocytic Leukemia Executive Summary
Acute Lymphocytic Leukemia Overview
Acute Lymphocytic Leukemia Pipeline Therapeutics
Acute Lymphocytic Leukemia Therapeutic Assessment
Acute Lymphocytic Leukemia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acute Lymphocytic Leukemia Collaboration Deals
Late Stage Products (Phase III and Phase II/III)
JZP-458: Jazz Pharmaceuticals
Mid Stage Products (Phase II)
CPX-351: Jazz Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
UCART22: Cellectis
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
JZP-341: Jazz Pharmaceuticals
Inactive Products
Acute Lymphocytic Leukemia Companies
Acute Lymphocytic Leukemia Products
Acute Lymphocytic Leukemia Unmet Needs
Acute Lymphocytic Leukemia Market Drivers and Barriers
Acute Lymphocytic Leukemia Future Perspectives and Conclusion
Acute Lymphocytic Leukemia Analyst Views
Acute Lymphocytic Leukemia Companies
Appendix

For further information on the Acute Lymphocytic Leukemia Pipeline therapeutics, reach out to Acute Lymphocytic Leukemia Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024

Hour To Midnight Unveils New Website to Enhance Customer Experience for Escape Room Enthusiasts

Hour To Midnight is thrilled to announce the launch of its newly revamped website. This update represents a significant leap forward in how the company engages with its customers, offering an improved online experience that mirrors the adventure and mystery of its physical escape rooms. Situated at the heart of Portland’s entertainment scene, Hour To Midnight has consistently set the bar high for immersive escape room experiences. Now, with a newly updated website that’s as engaging as its games, the company aims to make discovering and booking escape room adventures easier and more enjoyable than ever.

The new website, accessible at Hour To Midnight, has been meticulously designed with the user in mind, featuring streamlined navigation, detailed game descriptions, and an effortless booking system. This digital facelift not only showcases the unique themes and thrilling narratives that Hour To Midnight is known for but also provides valuable resources for both first-timers and seasoned escape room players. From behind-the-scenes insights to tips for a successful escape, the website is poised to become a go-to hub for the escape room community in Portland and beyond.

Ed Wolf, a spokesperson for Hour To Midnight, expressed excitement about the launch: “Our mission has always been to deliver unforgettable escape room experiences. With our new website, we’re now able to extend this mission into the digital realm, making it easier for our customers to connect with us and each other. We’ve invested in creating a platform that not only looks great but also provides all the information and functionality needed to ensure a seamless customer journey from start to finish.”

This website revamp comes at a time when the demand for unique and interactive entertainment options, such as escape rooms, is on the rise. Recognizing the importance of an online presence that accurately reflects the quality and creativity of its escape rooms, Hour To Midnight’s new website also includes features like an integrated blog and social media feeds, keeping visitors up-to-date with the latest news, events, and special promotions.

As Hour To Midnight looks to the future, the new website marks the beginning of a new chapter in its journey to provide top-tier entertainment in Portland. The company invites both new and returning customers to explore the site and discover the perfect escape room adventure. With a lineup of games that challenge the mind and spark the imagination, Hour To Midnight is ready to continue its tradition of offering an exceptional escape room experience, both on and off the screen.

For media inquiries and further information about Hour To Midnight – Room Escape Games and its new website, please visit: hourtomidnight.com

Media Contact
Company Name: Hour to Midnight – Escape Rooms Portland
Contact Person: Ed Wolf
Email: Send Email
Phone: (503) 673-3948
Address:11525 NE Halsey St
City: Portland
State: OR
Country: United States
Website: https://www.hourtomidnight.com/

Biotech Bright Spots: Coeptis Therapeutics (COEP) And 3 Hidden Treasures

Coeptis Therapeutics Holding Inc. (NASDAQ: COEP) stands tall as a vanguard in the allogeneic cell therapy arena, spearheading groundbreaking solutions for patients battling cancer and other formidable conditions. Let’s embark on a journey to explore their remarkable story.

Genesis Of Innovation AT COEP:

Founded in 2017, Coeptis Therapeutics swiftly emerged as a beacon of progress, headquartered in the strategic heart of Wexford, PA. Their unwavering focus is to revolutionize patient outcomes in the fight against cancer. Their first-in-class, proprietary allogeneic NK cell therapy, targeting viral infections, exemplifies their commitment to pioneering solutions.

Leadership With Vision:

At the helm stands Dave Mehalick, Chairman, President, and CEO, who spearheads Coeptis’ transformative initiatives with unwavering determination. Brian Cogley, the Chief Financial Officer, ensures strategic financial stewardship, guiding the company towards sustainable growth.

A Fertile Ground For Growth:

The cell therapy market, particularly in the realm of cancer treatment, was valued at USD 17.04 billion in 2023. This sector is expected to witness a remarkable CAGR of 17.05% from 2024 to 2029, fueled by factors like rising chronic diseases, advancements in gene editing, and the inherent advantages of allogeneic therapies (enhanced quality, cost-effectiveness, and donor flexibility).

Industry Trailblazers:

While Coeptis Therapeutics leads the charge, they are not alone in paving the way. Other industry trailblazers stand alongside them, collectively shaping the future of this promising field:

– Gamida Cell Ltd. (NASDAQ: GMDA) pioneers cell therapy, utilizing proprietary NAM technology to boost cell efficacy. They aim to create curative allogeneic cell therapies for hematologic malignancies, leveraging the power of enhanced cells.

– Absci Corporation (NASDAQ: ABSI) innovates AI-driven drug development, merging scalable wet lab tech for enhanced biologics, hastening patient access. Their Integrated Drug Creation platform optimizes multiple drug traits, expediting clinic entry and ensuring success.

– Fate Therapeutics, Inc. (NASDAQ: FATE) pioneers clinical-grade iPSC-derived immunotherapies for cancer and autoimmune diseases. Their platform produces multiplex-engineered cells, including NK and T-cell candidates with synthetic controls like CARs, enhancing therapeutic potential.

Unlocking The Potential Of Cell Therapies:

Coeptis Therapeutics is relentlessly pursuing innovation, evident in its diverse pipeline of cutting-edge therapies. Let’s delve deeper into their remarkable assets:

– Licensed Proprietary Cell Expansion & Differentiation Platform: This forms the bedrock of Coeptis’ groundbreaking solutions, empowering the development of innovative cell therapies through proprietary technology.

– DVX-201: This pioneering allogeneic NK cell therapy specifically targets refractory acute myeloid leukemia, offering a beacon of hope for patients in dire need.

– SNAP-CAR Platform: This novel approach revolutionizes the fight against cancer by enabling precise targeting of multiple cancer antigens using engineered immune cells.

– GEAR-NK: This gene-edited autologous NK cell therapy unleashes the potential of personalized medicine, designed to enhance patient outcomes in cancer treatment.

Through this stellar portfolio, Coeptis tackles inherent allogeneic therapy challenges with ingenuity and precision. Strategies like pooled donor manufacturing ensure scalability, cost-effectiveness, and consistent production, raising the bar for patient care.

Fueling Innovation Through Synergy:

Recognizing the power of collaboration, Coeptis forges alliances with industry leaders like Deverra Therapeutics. This collaborative spirit accelerates novel cell therapy development, amplifying Coeptis’ impact in immuno-oncology and fostering an environment of innovation.

The partnership with Deverra Therapeutics marks a significant step forward, reshaping the allogeneic cell therapy landscape. Coeptis gains access to a scalable immunotherapy platform, expanding its reach and capabilities within the market.

A Bright Future Ahead:

Despite recent market fluctuations, analysts express strong confidence in the trajectory of Coeptis Therapeutics. They cite substantial upside potential and unanimously recommend buying the stock. Considering the high $6 price target, the potential upside of COEP could be as high as 1250%.

Strong insider ownership further bolsters investor sentiment, solidifying Coeptis’ position as a compelling opportunity within the biotech sector.

Anticipated Growth Drivers For Coeptis:

– Clinical Milestone Anticipation: Positive top-line data from pivotal trials is expected to drive investor enthusiasm and confidence in Coeptis’ therapies.

– Expansion Of Pre-Clinical Portfolio: Diversifying their asset pipeline will foster long-term growth and revenue streams.

– Innovative Cell Therapy Platform: Integrating new target-specific CARs will pave the way for next-generation therapies.

– Strategic Partnership Pursuits: Collaborations with industry leaders can expedite product delivery and boost investor confidence.

Looking Ahead:

The future for Coeptis is bright. Anticipated milestones like top-line data from pivotal trials and the expansion of their pre-clinical portfolio are expected to fuel investor enthusiasm and solidify Coeptis’s position as a leader in the allogeneic cell therapy space. Their dedication to developing innovative platforms and forging strategic partnerships will further accelerate their progress, unlocking the potential of this transformative technology and bringing hope to patients battling debilitating diseases.

Read More About COEP At https://www.stockstelegraph.com/coep

Sources

https://coeptis.investorroom.com/2024-02-07-Coeptis-Therapeutics-to-Pursue-Phase-2-Program-Using-Proprietary-First-in-Class-Allogeneic-NK-Cell-Therapy-for-the-Treatment-of-Viral-Infections

https://www.pharmaceutical-technology.com/data-insights/dvx-201-coeptis-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/

https://coeptistx.com/our-science/snap-car-t/

https://coeptis.investorroom.com/2021-05-18-Coeptis-Pharmaceuticals-Enters-into-Exclusive-Option-Agreements-with-VyGen-Bio-to-Co-develop-Technologies-Designed-to-Improve-the-Treatment-of-CD38-Related-Cancers

https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html

https://www.marketbeat.com/stocks/NASDAQ/COEP/price-target/

https://www.expertmarketresearch.com/reports/cell-and-gene-therapy-cgt-market

Disclaimer:

This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. Million News Media Inc. is not-a-registered-investment-advisor. Million News Media Inc. is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Million News Media Inc., its wholly owned subsidiaries, websites and social media platforms accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on February 21, 2024 till February 23, 2024, Million News Media Inc. has been compensated $24,000 (for three days) for coverage of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) by BOTANITOM. Million News Media Inc. and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. Million News Media Inc. will not update its purchases and sales of this stock in any future postings on Million News Media Websites and social media channels including its own and other forums they may post. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” “project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Million News Media Inc. does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Media Contact
Company Name: Million News Media Inc
Contact Person: Zeeshan Shabbir
Email: Send Email
Country: United States
Website: https://millionnewsmedia.com/

Introducing the Simplified CFD Trading App: AAA Trading

AAA Trading has introduced a new CFD trading app. The new app enables trading in different markets. Users can open the app to access financial instruments like stocks.

Hong Kong – AAA Trading has launched its new CFD trading app. It is unlike other trading platforms because it is suitable for experienced and beginner traders.

The new app aligns with the AAA Trading mission of providing borderless trading. Although it is just an app, it offers all the functionality you will find in a desktop browser. AAA Trading does not charge a commission on CFD trading. The app also contains educational materials and trading tools to assist in making the right trading decisions.

Trading Instruments

Opening the new CFD Trading app reveals several helpful features for trading:

1. Forex

Use our forex trading app to access global currencies. The app allows you to speculate how two different currencies will perform against each other. You will have a winning trade if you guessed the price will rise and the price rises by the end of the contract.

This forex trading app can access more than 50 of the most popular currencies. We charge no commission for trading. You can trade 24 hours a day. Trading happens five days a week.

Our live pricing board keeps you updated on the latest happenings. Traders can rely on tight spreads from 0.0 pips. There’s a handy daily analysis board to help you with research. Leverage goes up to 1:1000.

2. Stocks

The app also allows members to trade in most leading stocks all over the world. We cater to retail stock traders. Our members can make CFD trades on stocks in a variety of sectors like tech and industrials. This gives you access to stocks like Apple and Amazon.

AAA Trading uses fractional shares, making it easier for users to start trading. Further, we do not charge any commission. We provide negative balance protection to ensure you don’t owe us money after your account balance reads nil. The platform offers leverage up to 1:20.

The app shows live pricing data. Spreads average are as low as 30. You can check the daily analysis tab to get insights on how stocks are performing.

3. Indices

AAA Trading app provides access to leading equity markets. Any membership level allows you to perform CFD trading in markets like NAS100. You can go long or short on an index of your choice.

We offer leverage up to 1:50. This allows you to trade any time even when you are short on cash. The hidden fees aren’t something to be concerned about either.

Our members have access to free analysis and news. Further, there is a live pricing board where they can view information on the most traded indices. Users can examine other educational materials, which helps in making accurate decisions.

Members even have access to an economic calendar they can use to track indices relevant to them.

4. Commodities

The app enables speculative trading on all the leading commodities like gold and Brent oil. Most users can trade on the AAA Trading app as it allows commodities trading with margins as low as $5. You may speculate on a wide variety of commodities at competitive spreads.

Leverage for commodities stands at 1:1000. This enables wider room for speculation because commodities are volatile. The greater price movement also allows members to receive greater returns on their investments.

Traders have access to a live prices board showing the most traded commodities. They can conduct research using the wide range of free news and analysis information. AAA Trading also provides an economic calendar tool for tracking commodities pricing.

5. Cryptocurrencies

Access all the leading cryptocurrencies including Bitcoin and Ethereum. Our AAA Trading app ensures no slippage so you get the prices you want every time. Trading is available 24 hours a day. You can trade for five business days.

You have peace of mind as the app provides free stop loss against open trades. Traders can access tight fixed trades from 0.01 pips. There is also negative balance protection for extra protection when trading.

AAA Trading does not charge commissions. They do not burden you with hidden fees either. Members can use the analytical tools to make better decisions.

Traders can take advantage of cryptocurrency volatility. This provides better options for going long or short. Volatility also opens up the chance to short-sell.

Mobile Trading Features

The CFD trading app makes it easy to trade. It is now possible to register, fund, and start trading within seconds.

You can open, modify, and close your positions with one click. AAA Trading has provided a simple way to log in to your accounts. This makes it easier to transfer funds from one account to another and shift between different devices.

The app retains the same functionality as the web platform. This includes the analysis and risk management tools.

Users will receive price alerts, notifications, and market news instantly. Considering you have access to real-time trading, you will never miss an opportunity to invest.

Types of Membership

Standard Account

Account holders have access to all trading instruments. Spreads on all major pips go as low as 1.5 pips. 0.01 lots is the minimum trade volume.

The standard account allows 40 lots as the maximum trade volume. The minimum deposit is $25. Leverage is slightly lower than the other account at up to 1:500. They have one free withdrawal monthly.

VIP Account

Trade in all instruments for pips as low as 0.0. Maximum and minimum trading lots are similar to the standard account. The minimum deposit is $2000. VIP account holders can withdraw twice per month for free.

How to Start

Head over to the Google Play Store.

Download and install the app.

Open the app and register.

Deposit some cash to start trading. Try the demo account before you start live trading if you are a beginner.

About AAA Trading

AAA Trading is a CFD trading platform. The company started running in 2017. We have committed our resources to delivering simplified CFD trading since our beginning. The app helps our clients achieve their investment goals. This new CFD trading app also allows our users to access more markets.

Media Contact
Company Name: Famous Worldwide Trading Limited
Contact Person: Adrian Reiff
Email: Send Email
Address:UNIT C6 17/F TML TOWER3 HOI SHING ROAD
City: TSUEN WAN
State: NEW TERRITORIES
Country: HongKong
Website: https://www.aaatrading.net/

Biotech Innovation: Coeptis Therapeutics (COEP) And 3 Companies Changing The Game

Coeptis Therapeutics Holding Inc. (NASDAQ: COEP) is a biopharmaceutical company making waves in the world of cell therapy, particularly focusing on allogeneic approaches for cancer and other serious diseases. Led by Dave Mehalick (Chairman, President, and CEO) and Brian Cogley (CFO), Coeptis is recognized as a leader in this innovative field.

A Growing Market For COEP

Unlike autologous therapies that use a patient’s own cells, allogeneic therapies utilize cells from healthy donors, offering advantages like:

– Enhanced Product Quality: Standardized cells ensuring consistency.

– Reduced Costs: Off-the-shelf approach minimizes processing expenses.

– Flexibility In Donor Selection: Increased availability of compatible cells.

The cell therapy market, valued at $17.4 billion in 2023, is expected to grow at a CAGR of 17.05% until 2029, fueled by factors like rising chronic diseases and advancements in gene editing.

Key competitors of COEP include Mersana Therapeutics (MRSN), Arbutus Biopharma (ABUS), and Ocular Therapeutix (OCUL).

Mersana Therapeutics, Inc. (NASDAQ: MRSN)

Mersana Therapeutics pioneers novel antibody-drug conjugates (ADCs), aiming to address patients’ unmet needs. Their focus on proprietary ADC platforms, Dolasynthen and Immunosynthen, fuels a diverse pipeline of cancer treatments. Committed to innovation, they strive to bring hope to those awaiting effective therapies, driving progress in clinical biopharmaceuticals.

Arbutus Biopharma Corporation (NASDAQ: ABUS)

Arbutus Biopharma applies virology expertise to innovate therapies for chronic hepatitis B virus (cHBV), aiming for a functional cure. Strategies involve suppressing HBV DNA, reducing surface antigen, and enhancing HBV-specific immune responses. Their pipeline features imdusiran (AB-729), showing promise in Phase 2a combination trials, alongside AB-101, an oral PD-L1 inhibitor.

Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Ocular Therapeutix, Inc. pioneers treatments utilizing ELUTYX, their bioresorbable hydrogel-based technology. Their flagship product, DEXTENZA, an FDA-approved corticosteroid, addresses ocular inflammation, post-surgical pain, and allergic conjunctivitis itching. They focus on formulating, developing, and commercializing innovative solutions for various eye conditions.

Collaboration Fueling Innovation:

Coeptis understands the power of collaboration. Its partnership with Deverra Therapeutics brings together expertise and resources to accelerate development and expand reach in immuno-oncology, offering access to a scalable immunotherapy platform.

Cutting-Edge Pipeline:

Coeptis boasts a diverse pipeline showcasing their innovative spirit:

– Licensed Proprietary Cell Expansion & Differentiation Platform: This technology forms the foundation for developing their cell therapies.

– DVX-201: A first-of-its-kind allogeneic NK cell therapy targeting acute myeloid leukemia.

– SNAP-CAR Platform: Enables targeting multiple cancer antigens with engineered immune cells.

– GEAR-NK: A gene-edited autologous NK cell therapy for improved cancer treatment outcomes.

By employing smart strategies like pooled donor manufacturing, Coeptis tackles challenges associated with allogeneic therapy, aiming for scalability, cost-efficiency, and consistency in patient care.

Investor Confidence:

Despite market fluctuations, analysts remain bullish on Coeptis, citing its significant upside potential and unanimous buy ratings with a high $6 price target, implying a potential 1250% increase. Strong insider ownership further strengthens investor confidence.

Coeptis’ Growth Catalysts:

Investors can expect key events propelling Coeptis’ growth, including:

– Top-line data from pivotal trials: Demonstrating the efficacy and safety of their therapies.

– Expansion of the pre-clinical portfolio: Building a robust pipeline for the future.

– Integration of target-specific CARs: Expanding the capabilities of their platform.

– Strategic partnership pursuits: Collaborating with industry leaders for further advancement.

Standing At The Forefront:

Coeptis Therapeutics stands at the forefront of allogeneic cell therapy, offering transformative solutions for cancer and other serious diseases. With a robust pipeline, strategic partnerships, and a commitment to innovation, Coeptis presents an exciting opportunity for investors seeking exposure to this promising field.

Read More About COEP At https://www.stockstelegraph.com/coep

Sources

https://coeptis.investorroom.com/2024-02-07-Coeptis-Therapeutics-to-Pursue-Phase-2-Program-Using-Proprietary-First-in-Class-Allogeneic-NK-Cell-Therapy-for-the-Treatment-of-Viral-Infections

https://www.pharmaceutical-technology.com/data-insights/dvx-201-coeptis-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/

https://coeptistx.com/our-science/snap-car-t/

https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html

https://www.marketbeat.com/stocks/NASDAQ/COEP/price-target/

https://www.expertmarketresearch.com/reports/cell-and-gene-therapy-cgt-market

Disclaimer:

Media Contact
Company Name: Million News Media Inc
Contact Person: Zeeshan Shabbir
Email: Send Email
Country: United States
Website: https://millionnewsmedia.com/